AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for AbbVie Inc. (ABBV) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.
Model is in the production pipeline since April 29, 2015.
Market data for ABBV model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for ABBV.
Model is being retrained on a regular basis.
|% Held by Insiders||0.07%|
|% Held by Institutions||70.29%|
|EPS (last reported FY)||$5.60|
|EPS (last reported Q)||$1.87|
|EPS, estimated (last reported Q)||$1.80|
|Total revenues||$28 B|
|Net income||$5 B|